Zejing pharmaceutical: an advance loss of 372 million yuan to 455 million yuan in 2021
Zejing pharmaceutical announced its annual performance loss forecast for 2021. The company expects a net loss of 372 million yuan to 455 million yuan in 2021. During the reporting period, the company was in the early stage of drug commercialization and needed to invest more in early stage market development and academic promotion activities; At the same time, the company's new drug R & D pipeline is further enriched, and several innovative drugs are in key clinical trials. It is estimated that the R & D cost in 2021 will be about 472 million yuan.
This text is a result of machine translation.
Related companies：
Briefing May 24, 2022 02:24 PM
· Healthcare
Zelensky called on the international community to provide funds for Ukraine's reconstruction, which is expected to cost $500 billion
In-depth
Technology
Successful Multinational Corporations in China Series: Qualcomm China
Since China's reform and opening-up, many multinational corporations and groups have achieved success in China. They have not only been successful in their fields, but some also benefitted from wise M&A moves or investments. To answer these questions EqualOcean launches its Successful Multinational Corporations in China and analyzes the critical points of investing in China for investors and people interested in such a topic.
Jun 25, 2022 02:02 PM
Briefing May 21, 2022 06:44 AM
· Financials
913 companies have been investigated by public funds since the second quarter, and the six top flow fund managers focus on the leaders of subdivided industries
May 02, 2022 07:50 PM
Apr 18, 2022 09:14 PM
Apr 18, 2022 06:30 PM
Apr 11, 2022 08:42 PM
In-depth
Healthcare
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
Briefing Apr 18, 2022 10:18 PM
· Technology
A number of enterprises on the science and innovation board are listed on the "white list" of key enterprises for operation guarantee and transfer
Briefing Feb 07, 2022 06:49 PM
· Healthcare
Fengtai District of Beijing will lift the epidemic prevention zone of the whole region from now on.
Briefing Jan 14, 2022 02:18 PM
· Healthcare
Hong Kong stocks continued to rise in the anti epidemic sector, and Junshi biology rose nearly 17%
See more
Read next
In-depth
Technology
Successful Multinational Corporations in China Series: Qualcomm China
Jun 25, 2022 02:02 PM
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.